Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Major Discovery; Increasing the Effectiveness of Orally Administered CBD
In a recent human clinical trial, HYPER-H21-2, DehydraTECH™-CBD reduced arterial stiffness, potentially broadening Lexaria's application's ability to treat cardiovascular and other diseases beyond hypertension Lexaria’s patented technology DehydraTECH improves how APIs enter the bloodstream –making multiple benefits possible such as increased delivery speed, increase in brain absorbency, higher bioavailability, and lower costs The company has patent protection received for delivery of nicotine, vitamins, NSAIDs, terpenes and cannabinoids; and patents pending for delivery of estrogen, testosterone, PDE5 inhibitors, antiviral drugs and more Oral absorption is the most convenient and widely used administration route for taking medications. Decades of research have advanced…